

PATIENT INFORMATION
PATIENT NAME: _____ **PHONE:** _____

DATE OF BIRTH: _____ **SEX:** ☐ M ☐ F **HEIGHT:** _____ **WEIGHT:** _____ ☐ LBS ☐ KG

ALLERGIES: _____ **PREFERRED CLINIC:** _____

REFERRAL STATUS: ☐ NEW REFERRAL ☐ ORDER CHANGE ☐ ORDER RENEWAL

DIAGNOSIS & CLINICAL DOCUMENTATION

- | | |
|---|---|
| <input type="checkbox"/> K50.00 Crohn's Disease – small intestine | <input type="checkbox"/> M05. ____ Rheumatoid Arthritis with rheumatoid factor |
| <input type="checkbox"/> K50.10 Crohn's Disease – large intestine | <input type="checkbox"/> M06. ____ Rheumatoid Arthritis without rheumatoid factor |
| <input type="checkbox"/> K50.80 Crohn's Disease – small & large intestine | <input type="checkbox"/> M45. ____ Ankylosing Spondylitis (AS) |
| <input type="checkbox"/> K50.90 Crohn's Disease, unspecified | <input type="checkbox"/> M45.A__ Non-Radiographic Axial Spondyloarthritis (nr-axSpaA) |
| <input type="checkbox"/> L40.0 Psoriasis vulgaris | <input type="checkbox"/> M46.8__ Other specified inflammatory spondylopathies |
| <input type="checkbox"/> L40.5__ Psoriatic Arthritis (PsA) | |
| <input type="checkbox"/> L40.9 Psoriasis, unspecified | |

☐ ICD-10 CODE: _____ DESCRIPTION: _____

REQUIRED DOCUMENTATION

- | | | | | |
|--|--|---|---|--|
| <input type="checkbox"/> Insurance Information | <input type="checkbox"/> List of Medications | <input type="checkbox"/> Tried & Failed Therapies | <input type="checkbox"/> Most Recent History & Physical | <input type="checkbox"/> Negative TB screening |
|--|--|---|---|--|

MEDICATION ORDER

- ☐ **LOADING:** Cimzia® (certolizumab pegol) 400mg subcutaneous injection at week 0, week 2 and week 4
- ☐ **MAINTENANCE:** Cimzia® (certolizumab pegol) 200mg subcutaneous injection every 2 weeks
- ☐ **MAINTENANCE:** Cimzia® (certolizumab pegol) 400mg subcutaneous injection every 4 weeks
- ☒ **REFILL X 12 MONTHS UNLESS OTHERWISE NOTED HERE:** _____

Patient to be observed for 30 minutes following the first administration.
 In the event of an adverse reaction occurring in the infusion clinic, utilize the Immersiv Health adverse reaction protocol.

PRESCRIBER INFORMATION
PROVIDER NAME: _____ **NPI #:** _____

EMAIL: _____ **PHONE:** _____ **FAX:** _____

ADDRESS (INCLUDE CITY, STATE, ZIP): _____

SUPERVISING PHYSICIAN: _____ **CONTACT NAME:** _____
(IF APPLICABLE)
SIGNATURE: _____ **DATE:** _____
(NO STAMPS)

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN